Preclinical Transient Ischemic Attack Research Services

A transient ischemic attack (TIA), also known as a "mini stroke," is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. TIA is a critical early warning sign of stroke, with up to 23% of ischemic stroke patients experiencing a TIA within hours to days preceding their stroke. Despite its significance, TIA remains largely understudied. Evidence suggests that TIA-induced tissue changes can range from an ischemia-tolerant state to clinically silent infarction. Moreover, repeated TIAs may be linked to cognitive decline and brain atrophy.

Ace Therapeutics is a leading provider of preclinical TIA studies dedicated to advancing the development of effective therapeutics. Ace Therapeutics is equipped with advanced facilities and resources to support TIA research projects.

Custom Animal Models of TIA

Our TIA models encompass a range of species, including both small animals such as mice and rats, as well as large animals such as pigs and monkeys. Our expertise in TIA models enables us to select the most appropriate models for specific research needs.

Types of Drugs We Can Develop for TIA

With our extensive experience and expertise in drug discovery, we assist our clients in discovering new targets and developing novel therapies for TIA.

Preclinical Evaluation of TIA Therapeutics

Ace Therapeutics provides highly predictive TIA models, carefully executed assessments, and detailed observational measurements to determine the effects of novel therapeutics for TIA.

Monitoring of cerebral blood flow (CBF) in TIA

• We use laser Doppler flowmetry (LDF) to capture dynamic changes in cerebral blood flow in real timeduring TIA modeling to provide detailed information about cerebral microcirculation, including parameters such as blood flow velocity, blood viscosity, and tissue oxygenation status. This data not only helps clients understand the mechanisms of blood flow changes during TIA, but can also provide the basis for preclinical drug development to optimize treatment strategies.

Magnetic resonance imaging (MRI) in TIA

• We can use different MRI sequences to assess the state of the brain in animal models of TIA. In diffusion-weighted imaging (DWI), areas of the brain where water diffusion is restricted due to cytotoxic edema—often associated with ischemic events—will manifest as regions of increased signal intensity. This characteristic enables us to facilitate the early detection of ischemic lesions, even during the brief symptomatic phase of TIA, providing valuable information to our clients.

Histological Evaluation of TIA

• By systematically analyzing stained sections, we aim to correlate the observed histological changes with the manifestations of TIA, thereby helping clients with drug evaluations.

Ace Therapeutics' industry-leading models and comprehensive assessments provide deep insights to advance your preclinical TIA research into the clinical development stage. Partner with us to unlock the potential of your program and advance the development of therapies for TIA. Please do not hesitate to contact us.

1. Wang, J., et al. (2020). Animal models of transient ischemic attack: a review. Acta Neurologica Belgica, 120, 267-275.

• Preclinical Ischemic Stroke Research Services
• Preclinical Hemorrhagic Stroke Research Services